PRAME and Breast Cancer Outcomes
Author Information
Author(s): Epping M T, Hart A A M, Glas A M, Krijgsman O, Bernards R
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Is PRAME expression associated with clinical outcomes in breast cancer patients?
Conclusion
PRAME expression is a prognostic marker for poor clinical outcomes in breast cancer.
Supporting Evidence
- PRAME expression levels were correlated with increased rates of distant metastases.
- High PRAME expression was associated with decreased overall survival.
- PRAME was identified as an independent marker of shortened metastasis-free interval.
Takeaway
This study found that higher levels of a protein called PRAME in breast cancer patients are linked to worse survival rates.
Methodology
The study analyzed PRAME gene expression in 295 breast cancer patients and correlated it with clinical outcomes using survival analysis.
Limitations
The study may not account for all variables affecting survival, and results may not be generalizable to all breast cancer populations.
Participant Demographics
Patients were women diagnosed with primary invasive breast carcinoma, aged 52 years or younger.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website